Zanubrutinib, Obinutuzumab Combined With Lenalidomide (ZGR) for the Treatment of Untreated Follicular Lymphoma

NCT07299149 · clinicaltrials.gov ↗

PHASE2

Phase

RECRUITING

Status

34

Enrollment

OTHER

Sponsor class

Conditions

Follicular Lymphoma

Interventions

DRUG: Induction Therapy: Zanubrutinib, obinutuzumab, lenalidomide
DRUG: Maintenance therapy: Zanubrutinib, lenalidomide

Sponsor

Institute of Hematology & Blood Diseases Hospital, China